An observational study in Sickle Cell Disease and Vaso-occlusive Crisis, sponsored by University of Pennsylvania. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by University of Pennsylvania · Observational
This study aims to characterize sex differences in the pathophysiology of vaso-occlusive crises (VOC) occurring among individuals with sickle cell disease (SCD).
1,104 studies on the registry are indexed under Anemia, Sickle Cell; 236 are open to participants now.
This study's enrollment of 52 is below the median of 100 across 288 observational studies indexed under Anemia, Sickle Cell.
Browse Anemia, Sickle Cell studies →University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.
Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Individual with sickle cell disease receiving care for vaso-occlusive pain episodes.
Exclusion Criteria:
C-reactive protein level
Serum level of hs-CRP
Time frame: 1 month
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pennsylvania